Infectious
disease was the leading cause of death in the United States until the discovery
of antibiotics to treat bacterial infections in 1920’s. Penicillin proved a
powerful weapon to fight disease and was even effective in combating deadly
staph infections. Staph is a common bacterium, found on the skin or in the nose
of even healthy individuals but becomes serious if it invades deeper into the
skin, blood or organs. The malevolent staph bacteria developed resistance to
penicillin in the 1940’s and medical science was forced to find to another
antibiotic, methicillin to treat staph. Even so, by the 1960s staph had become
resistant to it too and the virulent strain of staph infection, MRSA
(Methicillin-resistant Staphylococcus aureus) was upon us. Health care
professionals have now been combating MRSA for over 50 years.
The
Centers for Disease Control and Prevention (CDC) estimated 80,500 cases of
invasive MRSA and 11,000 deaths in the US in 2011. However, the CDC tracks only
invasive MRSA infections where the staph bacteria have reached the bloodstream
or invaded internal organs. In same year there were nearly 460,000
hospitalizations involving a MRSA diagnosis and data suggests these
hospitalizations resulted in over 20,000 deaths. The inability to detect or
track MRSA cases is complicating efforts by public health officials to develop
prevention strategies and keep the bacteria from threatening vast new segments
of the population.
In
addition to the serious individual and public health issues caused by MRSA, it
also places a severe financial impact on private and public health care
systems. Early detection is vital to effectuate protective measures for
patients and stop the spread of the disease. Currently there is no cost
effective system early detection system for MRSA in the patient or in the rooms
of a healthcare building. Zenosense, Inc. is focused on developing this much
needed MRSA early detection device.
The
Zenosense, Inc. patent-pending device is being designed to sample air and
continuously monitor for the airborne Volatile Organic Compounds (“VOCs”)
signature emitted by MRSA. This cutting-edge detection device is intended to be
produced as a low cost unit to be worn by patients and medical staff. In the
event of any infection, the MRSA device will detect the VOCs produced by the
infected person and emit an audio/visual alarm. There is also a network
monitored hard wired detection device planned to be positioned in the room with
a magnifier for MRSA presence. Zenosense has actively been developing these
products since December 2013 for this multi-million dollar market. As Zenosense
has moved forward in development they have put multiple strategic relationships
in place with hospitals, universities, and the high tech private sector to
facilitate both research and roll out.
These
relationships have led the company into another lucrative untapped market.
Zenosense believes a vast global opportunity exists for a low cost lung cancer
detection device used at point of care. A device that matches or exceeds the
accuracy of a Tomography scan would be in universal demand as a complimentary,
indicative test to increase early detection and achieve best outcomes.
Once
to market these early detection devices can easily save lives, save money for
public and private health facilities and potentially deliver vast rewards for
Zenosense investors.
For
more information, visit: www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment